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Background 
Rapid antimicrobial susceptibility surveillance is essential in the clinical 
methicillin-resistant Staphylococcus aureus (MRSA) infection control as the rise in 
MRSA-related mortalities and the increase of multi-drug non-susceptible strains have 
become apparent. The use of next generation sequencing (NGS) technology allows 
DNA-based genome profiling in clinical MRSA outbreaks and requires less laborious effort, 
compared to conventional methods, for the purpose of MRSA antimicrobial susceptibility 
surveillance. This study aimed to retrospectively elucidate the correlations between the 
genome and phenotype in clinical MRSA gentamicin (GEN), clindamycin (CLI), and 
minocycline (MIN) susceptibility using NGS technology. The benefit of antimicrobial 
susceptibility surveillance using NGS technology would be in the greater effect to these 
commonly administered antimicrobials in MRSA infections. 
 
Methods 
Ninety two MRSA strains were isolated from individual inpatients treated in 
Hiroshima University Hospital, Hiroshima, Japan during two separate time periods: 
October – December 2009 (36/92) and January 2013 – March 2014 (56/92). The minimum 
inhibitory concentration (MIC) data for GEN, CLI, and MIN (GEN-MIC, CLI-MIC, 
MIN-MIC) of the strains were categorized according to the modified standards of the CLSI 
M100-S19 guideline during the procedure. A GEN non-susceptible strain was defined as a 
strain which exhibited ≥8 mg/L of GEN-MIC level. A CLI non-susceptible strain was defined 
as a strain which exhibited ≥2 mg/L of CLI-MIC level. A MIN non-susceptible strain was 
defined as a strain which exhibited >8 mg/L MIN MIC level. Genomic DNAs were isolated 
from the strains and sequenced using an Illumina® MiSeq sequencer. The sequence data of 
each strain was assembled using SPAdes to obtain its de novo whole-genome assembly. An in 
silico analysis using ResFinder online gene-mapping tool was performed at >90% identity 
similarity and >60% query length thresholds to obtain the genomic antimicrobial 
susceptibility profile from each of the assembly. This procedure allowed the identification of 
two genes related in the acquired aminoglycoside susceptibility, which were aac(6’)aph(2”) 
and spc, a gene related in the acquired macrolide-lincosamide-streptogramin B susceptibility, 
which was ermA, and a gene related in the acquired tetracycline susceptibility, which was 
tetM. The resulting profile was analyzed together with GEN, CLI, and MIN-MIC levels. The 
χ2 test was performed to describe the associations between individual in silico detection of 
acquired antimicrobial susceptibility genes and GEN, CLI, and MIN-MIC levels at its 
respective non-susceptible threshold. The Fisher exact test of independence was performed 
and the Cramer’s V coefficient was calculated to describe the correlations between the 
genomic detection patterns and the MIC levels of MRSA strains as observed in GEN, CLI, 
and MIN. 
 
Results & Discussion 
Non-susceptibility to GEN was found in 75.00% (69/92) strains. Most of these strains 
(91.30%, 63/69) were shown to exhibit >16 mg/L of GEN-MIC level. Non-susceptibility to 
CLI was found in 68.48% (63/92) strains. Most of these strains (80.95%, 51/63) were shown 
to exhibit >4 mg/L of CLI-MIC level. Non-susceptibility to MIN was found in 40.22% (37/92) 
strains and all of these strains were shown to exhibit >8 mg/L of MIN-MIC level. The in 
silico antimicrobial susceptibility detection revealed 63.04% (58/92) strains were 
aac(6')aph(2")+, 77.17% (71/92) strains were spc+, 77.17% (71/92) strains were ermA+, and 
69.57% (64/92) strains were tetM+. All of spc+ strains were ermA+ strains. Associations 
between aac(6’)aph(2”) detections and GEN MIC levels (p <0.001), ermA detections and 
CLI-MIC levels (p <0.001), and tetM detections and MIN-MIC levels (p <0.001) were 
revealed in this study. Six gene detection patterns were identified and were consisted of 
aac(6')aph(2")+,spc+,ermA+,tetM+ as seen in 45.65% (42/92) strains; 
aac(6')aph(2")+,spc+,ermA+,tetM- as seen in 1.09% (1/92) strains; 
aac(6')aph(2")-,spc+,ermA+,tetM+ as seen in 23.91% (22/92) strains; 
aac(6')aph(2")-,spc+,ermA+,tetM- as seen in 6.52% (6/92) strains; 
aac(6')aph(2")+,spc-,ermA-,tetM- as seen in 16.30% (15/92); and 
aac(6')aph(2")-,spc-,ermA-,tetM- as seen in 6.52% (6/92) strains. The 
aac(6’)aph(2”)+,spc-,ermA-,tetM+ and aac(6’)aph(2”)-, spc-,ermA-,tetM+ patterns were not 
found. The simultaneous detection patterns were correlated with GEN-MIC levels (φc= 0.398, 
p <0.001), CLI-MIC levels (φc= 0.448, p <0.001), and MIN-MIC levels (φc= 0.515, p <0.001). 
The predominating aac(6')aph(2")+,spc+,ermA+,tetM+ MRSA strains were shown to 
exhibit >16 mg/L GEN (40/42), >4 mg/L CLI (26/42), and >8 mg/L MIN-MIC levels (30/42) 
and its presence was shown to be in increasing trends between 2009 and 2013 – 2014. The 
genomic-phenotypic correlations analyses in this study provided an insight of a rapid 
antimicrobial detection in MRSA using in silico genomic antimicrobial susceptibility 
profiling. The correlation between the detection of aac(6')aph(2") and GEN-MIC level 
revealed in this study were comparable to that of a previous study. The study mentioned the 
importance to distinguish erythromycin and CLI non-susceptibility during ermA detection 
in MRSA strains due to the nature of erm class gene. Since the erythromycin susceptibility 
test was not examined in the routine examination in our hospital, it may limit to interpret 
the correlation analysis involving CLI-MIC level. Future study involving erythromycin 
would be warranted to improve the accuracy of this part of study result. Greater 
non-susceptibility of CLI in ermA+ MRSA involving aac(6')aph(2") and tetM genes was of 
unknown mechanism and future study addressing these findings should be warranted. The 
MIN-MIC level was shown to be correlated to the existence of tetM as supported by a 
previous study. This study suggest the detection of the emerging multidrug 
non-susceptibility strains among the clinical MRSA strains could be performed using in 
silico combined detection of aac(6’)aph(2”)-spc-ermA-tetM. Discrepancy occurred in this 
study could be attributed to the unidentified novel gene variants which may in turn were 
responsible in different non-susceptibility mechanisms. Combined use of NGS technology 
and other methodologies would effectively provide accurate and reliable information, as 
laboratory methods used to detect antimicrobial susceptibility and mechanism in MRSA 
with high sensitivity and specificity. 
 
